Recent news on Glatiramer

Sutton Heads to Second Short Track of 2007 Season  -  May 23, 2007
TruckSeries.com,51 Team COPAXONE (glatiramer acetate injection) Chevrolet Silverado fielded by Billy Ballew Motorsports. Billy Ballew Motorsports also fields the No.15

Natco Pharma launches Glatiramer Acetate  -  May 16, 2007
Myiris.com,Drug maker Natco Pharma (Q, N,C,F)* said on Wednesday that company strengthened its presence in neurology segment with the launch of Glatiramer Acetate.

Teva may face generic rival to Copaxone  -  May 20, 2007
Therapeutics Daily (subscription) (press release),Natco Pharma Ltd. of Hyderabad, India, said it would launch glatiramer acetate, the generic version of Copaxone, at about 40% of the price of the branded

Copaxone Treatment over Two Years after Short Term Induction with ...  -  May 4, 2007
PharmaLive.com (press release),The analysis, Reductions in Gd Enhancing Lesions Observed with Glatiramer Acetate Following a Brief and Low Dose Course of Mitoxantrone in Patients with

News For Your Web Site  -  May 6, 2007
dBusinessNews St. Louis (press release),LOUIS -- New data from a randomized, double-blind study showed that a combination of COPAXONE® (glatiramer acetate injection) along with the oral antibiotic

Treatment with Copaxone Plus Minocycline Showed Substantial ...  -  May 4, 2007
PharmaLive.com (press release),Current data suggest COPAXONE(R) (glatiramer acetate injection) is a selective MHC class II modulator. COPAXONE(R) is indicated for the reduction of the

Treatment with Copaxone Plus Minocycline Showed Substantial ...  -  May 4, 2007
PharmaLive.com (press release),KANSAS CITY, Mo, May 4, 2007 - New data from a randomized, double-blind study showed that a combination of Copaxone (glatiramer acetate injection) along

Kansas: Chevy NASCAR Truck Race Preview  -  Apr 25, 2007
PaddockTalk..."I am also very grateful to Team COPAXONE® (glatiramer acetate injection) for giving me the opportunity to conqueror the track that took so much away from

Disappointing Season Opener for Sutton  -  May 8, 2007
TruckSeries.com,51 Team COPAXONE (glatiramer acetate injection) Chevrolet Silverado as part of a four race deal with Billy Ballew Motorsports.

Copaxone sales soar as Teva enjoys earnings growth  -  May 3, 2007
Pharma Times (subscription),Group turnover was up 24% to $2.08 billion, with Copaxone (glatiramer acetate) bringing in $401 million, an increase of 22%, thanks to 18% growth in US

Sutton's Return Helps Make History  -  Apr 26, 2007
TruckSeries.com,51 Team COPAXONE® (glatiramer acetate injection) Chevrolet Silverado NASCAR Craftsman Truck for the running of the O’Reilly Auto Parts 250.

Ballew Breaking Boundaries  -  Apr 25, 2007
TruckSeries.com,51 Team COPAXONE (glatiramer acetate injection) Chevrolet Silverado. Sutton will be making her first start since Nashville in 2006 and is scheduled for

Kansas: Chevy NASCAR Truck Race Preview  -  26 Apr 2007
PaddockTalk..."I am also very grateful to Team COPAXONE® (glatiramer acetate injection) for giving me the opportunity to conqueror the track that took so much away from

Sutton's Return Helps Make History  -  26 Apr 2007
TruckSeries.com,51 Team COPAXONE® (glatiramer acetate injection) Chevrolet Silverado NASCAR Craftsman Truck for the running of the O’Reilly Auto Parts 250.

Higher-dose glatiramer reduces MS symptoms and relapses  -  Mar 28, 2007
Therapeutics Daily (subscription) (press release),NEW YORK (Reuters Health) - Glatiramer at a dose of 40-mg daily may reduce symptoms and relapses of relapsing-remitting multiple sclerosis (MS) more than

Data Published in Neurology Showed That Higher Dose of COPAXONE(R ...  -  Apr 17, 2007
Genetic Engineering News (press release),The study evaluated the effect of 40 mg of COPAXONE(R) (glatiramer acetate injection) given daily versus 20 mg of COPAXONE(R) on disease activity as

Kelly Sutton signs four-race deal with Ballew  -  Mar 31, 2007
Rotoworld.com51 Team COPAXONE (glatiramer acetate injection) Chevrolet Silverado beginning at the Kansas Speedway NASCAR Craftsman Truck Series event, the O'Reilly Auto

First Pharmacoeconomic Analysis with Long-Term Data Showed ...  -  Apr 11, 2007
PharmaLive.com (press release),...physical therapy/exercise and pharmacological treatment) alone and symptom management combined with COPAXONE(R) (glatiramer acetate injection),

MS Patients Not Receiving Medications To Slow Disease Progression ...  -  Apr 20, 2007
Medical News Today (press release),They are: interferon-1b (sold under the name Betaseron®), interferon-1a (Avonex®), glatiramer acetate (GA or Copaxone®), interferon-1a (Rebif®),

MS patients not receiving medications to slow disease progression  -  Apr 18, 2007
News-Medical.net,They are: interferon-1b (sold under the name Betaseron), interferon-1a (Avonex), glatiramer acetate (GA or Copaxone), interferon-1a (Rebif),

New One-Year Pharmacoeconomic Study Shows Avonex® Is Cost ...  -  Apr 18, 2007
Medical News Today (press release),Over the one-year period, use of disease-modifying therapies (interferon beta and glatiramer acetate) was almost always observed as monotherapy,

Glatiramer Acetate Multiple Sclerosis Treatment Posted By : Tobias ...  -  Mar 7, 2007
Business Portal 24 (press release),Glatiramer acetate is a myelin like protein. Its means or the method it has to fight MS haven't been totally figured, but it seems to act as an obstruction

Multiple Sclerosis Affects Less Than 1% Of The Population In The ...  -  Mar 22, 2007
PharmaLive.com (press release),...as a last-line therapy for relapse-remitting patients who have failed first- and second-line treatment with interferon beta or glatiramer acetate.

Wonder Drug To Be Blocked  -  Mar 17, 2007
Sky News,But older-generation drugs, interferons and glatiramer acetate are generally acknowledged as demonstrating about a 30-35% decrease in relapse rate against a

Initial Analysis of the Full Study Cohort Showed Treatment Did Not ...  -  Feb 27, 2007
Insurance News Net,27, 2007--Data from the full cohort of the PROMiSE study showed that treatment with COPAXONE(R) (glatiramer acetate injection) did not reach a significant

Post-Hoc Data Analyses Published in Annals of Neurology Found ...  -  Feb 27, 2007
Business Wire (press release),BUSINESS WIRE)--Data from the full cohort of the PROMiSE study showed that treatment with COPAXONE ® (glatiramer acetate injection) did not reach a

Post-Hoc Data Analyses Published in Annals of Neurology Found ...  -  Feb 27, 2007
PharmaLive.com (press release),BUSINESS WIRE)--Feb 27, 2007 - Data from the full cohort of the PROMiSE study showed that treatment with COPAXONE(R) (glatiramer acetate injection) did not

Christopher and Dana Reeve Foundation Awards Over One Million ...  -  Mar 23, 2007
PR Newswire (press release),Calgary, AB, Canada Enhancing neuroprotection and regeneration in spinal cord injury by the combination of minocycline and glatiramer acetate.

Teva shares rise on the promise of a strong 2007 and 2008  -  Feb 14, 2007
Pharma Times (subscription),As for Teva's branded products, multiple sclerosis drug Copaxone (glatiramer acetate) had another strong quarter with sales up 17% to $378 million,

Biogen Idec Increases Profits But Misses 4Q EPS Estimates  -  Feb 15, 2007
BioWorld Online,...digits for about two years, and among competitive products, Copaxone (glatiramer acetate, from Teva Pharmaceuticals Inc.) is growing at a faster clip.

Medical Edge: Plasma exchange used as treatment, not cure, for MS  -  Jan 27, 2007
Bryan College Station Eagle,An alternative to beta interferons is glatiramer acetate (Copaxone), which promotes the production of certain proteins, called cytokines, that can reduce

Stakeholder Insight: Multiple Sclerosis - Disease-modifying ...  -  Dec 20, 2006
Pharmaceutical Business Review...as a last-line therapy for relapse-remitting patients who have failed first- and second-line treatment with interferon beta or glatiramer acetate.

Pragmatic approach to MS  -  Jan 15, 2007
Stuff.co.nz,At present there is no cure but drugs such as glatiramer and beta interferon can slow its progression and muscle relaxants can help control some of the

Biogen Idec Initiates Phase III Clinical Program Of Oral Compound ...  -  Jan 15, 2007
Medical News Today (press release),CONFIRM will also include a glatiramer acetate (Copaxone®) reference comparator arm. Endpoints of both studies include evaluating the effect of BG-12 on

Stakeholder Insight: Multiple Sclerosis - Disease-modifying ...  -  Dec 20, 2006
Pharmaceutical Business Review...as a last-line therapy for relapse-remitting patients who have failed first- and second-line treatment with interferon beta or glatiramer acetate.

Diagnosis and Monitoring of Multiple Sclerosis: Focus on ...  -  Nov 27, 2006
Medscape (subscription)Khan and colleagues [6] studied prospective magnetic resonance spectroscopy in 18 relapsing-remitting MS patients on glatiramer acetate and 4 untreated

Clinical Trial Design  -  Nov 27, 2006
Medscape (subscription)...[2] For example, the Betaferon Efficacy Yielding Outcomes of a New Dose (BEYOND) trial compares 2 doses of interferon beta-1b with glatiramer.

Multiple Sclerosis Charity 'Bitterly Disappointed' at Scottish ...  -  Dec 11, 2006
netPR.pl (komunikaty prasowe),For people with severe relapsing remitting MS who do not respond to beta interferon, or to glatiramer acetate, there had been no licensed and effective

Multiple sclerosis treatment: Is combination therapy effective?  Nov 2, 2006
Interferon beta-1a (Avonex, Rebif) and glatiramer (Copaxone) are two drugs approved by the Food and Drug Administration for the treatment of relapsing ... -MayoClinic.com TODAY ON PHARMALIVE.COM  Sep 12, 2006
...comparing patients treated with immunomodulatory agents with untreated patients revealed that only treatment with COPAXONE(R) (glatiramer acetate injection ... -PharmaLive.com

Diagnosis and Monitoring of Multiple Sclerosis: Focus on ...  -  Nov 27, 2006
Medscape (subscription)Khan and colleagues [6] studied prospective magnetic resonance spectroscopy in 18 relapsing-remitting MS patients on glatiramer acetate and 4 untreated

Multiple Sclerosis Charity 'Bitterly Disappointed' at Scottish ...  -  Dec 11, 2006
PR Newswire UK (press release),For people with severe relapsing remitting MS who do not respond to beta interferon, or to glatiramer acetate, there had been no licensed and effective

Clinical Trial Design  -  Nov 27, 2006
Medscape (subscription)...[2] For example, the Betaferon Efficacy Yielding Outcomes of a New Dose (BEYOND) trial compares 2 doses of interferon beta-1b with glatiramer.

Teva Initiates Phase III Study To Confirm Increased Efficacy Of ...  Aug 7, 2006
Phase III study designed to confirm the positive results from the Phase II study which compared a new higher dose of 40 mg/day dose of glatiramer acetate (GA ... -Medical News Today

Teva Pharma Q2 Profit More Than Doubles; Adj. EPS Tops Street View ...  Aug 8, 2006
Phase III study designed to confirm the positive results from the Phase II study which compared a new higher dose of 40 mg/day dose of glatiramer acetate to ... -Trading Markets

Why are doctors so reluctant to prescribe treatment for MS?  Aug 3, 2006
The immuno modulators Avonex (interferon beta 1a), Betaferon (interferon beta 1b) and Copaxone (glatiramer) are drugs that reduce the frequency and severity of ... -Times Online

New hope for Multiple Sclerosis sufferers  Jul 21, 2006
Doctors have tried different methods to extend its effectiveness, and Dr Boggild wanted to test Copaxone, a glatiramer acetate which acts as a decoy by ... -Daily Mail - UK

New Hope for Patients With Aggressive MS  Jul 17, 2006
...regime, consisting of a limited course of mitoxantrone (an immunosuppressant normally used to treat cancer) followed by long-term glatiramer acetate (Copaxone(R ... -Drug Newswire

COPAXONE(R) Reduced Relapses By 75 Percent in Both Treatment-Naive ...  Jun 20, 2006
Both relapsing-remitting multiple sclerosis (RRMS) patients switching from Betaseron(R) (interferon beta-1b) to COPAXONE(R) (glatiramer acetate injection) and ... -PR Newswire

COPAXONE(R) Reduced Relapses By 75 Percent in Both Treatment-Naive ...  Jun 21, 2006
2006 | Both relapsing-remitting multiple sclerosis (RRMS) patients switching from Betaseron® (interferon beta-1b) to COPAXONE® (glatiramer acetate injection ... -PipelineReview.com

Teva Will Be Sole Promoter Of Azilect® For Parkinson's Disease In ...  Jul 15, 2006
...has demonstrated its capabilities in its neurological franchise through its sales efforts and significant success with COPAXONE® (glatiramer acetate injection ... -Medical News Today

Teva's stock wounded in ongoing drug wars  Jun 22, 2006
10-year long-term study showed that 92% of relapsing-remitting multiple sclerosis (RRMS) patients who stayed on Teva's Copaxone (a glatiramer acetate injection ... -MSN Money

Teva/Eisai: the End of an Alliance  Jul 13, 2006
...company has already demonstrated the capabilities of its neurological franchise through its significant success with Copaxone (glatiramer acetate injection ... -International News Service

Spotlight on Multiple Sclerosis  Jun 23, 2006
Another drug, glatiramer acetate, has a chemical make-up that appears to mimic a fragment of myelin, the insulation around the nerve axon. ... -FOX News



Long-Term Copaxone(R) Study Showed 92% Of Multiple Sclerosis ...  May 9, 2006
...study showed that 92 percent of relapsing-remitting multiple sclerosis (RRMS) patients in the study who remained on COPAXONE(R) (glatiramer acetate injection ... - Medical News Today

Multiple Sclerosis: New Insights and Trends  May 10, 2006
...beta-interferon-la (Avonex), subcutaneous beta-interferon-1a (Rebif), subcutaneous beta-interferon-1b (Betaseron), and glatiramer acetate (Copaxone). ... - AJNR (subscription)

Two MS drugs better than one?  Apr 17, 2006
National Institutes of Health, the study will determine if the combined use of Avonex (interferon beta-1a) once a week and Copaxone (glatiramer acetate) daily ... - myDNA.com

PharmaFrontiers Gets $23M To Advance MS Compound  Apr 17, 2006
...given as a one-hour infusion every month, while Avonex (interferon beta-1a), also from Biogen Idec, is dosed weekly, and Copaxone (glatiramer acetate), from ... - BioWorld Online (subscription)





Withdrawn multiple sclerosis drug is safe -studies  Mar 1, 2006
Conventional treatment with interferon beta and glatiramer acetate typically reduces the relapse rate of multiple sclerosis -- a serious disease in which the ... - Reuters AlertNet,

New studies highlight the benefit of anti-MS drug  Mar 2, 2006
Interferon-beta, a cytokine, has been used for some years as a therapy, along with other drugs such as glatiramer acetate and mitoxantrone. ... - Ars Technica,

Seronons 2005 Adjusted(i) EPS Increased by 34.6%  Feb 5, 2006
All patients in the REGARD (REbif vs Glatiramer Acetate in Relapsing MS Disease) study of Rebif(R) vs Copaxone have recently completed their first year of ... - MSN Money

Seronons 2005 Adjusted(i) EPS Increased by 34.6%  Feb 5, 2006
All patients in the REGARD (REbif vs Glatiramer Acetate in Relapsing MS Disease) study of Rebif(R) vs Copaxone have recently completed their first year of ... - MSN Money

Multiple sclerosis: Copaxone may offer protection from axonal ...  Jan 21, 2006
Clinical research data, published in the journal Multiple Sclerosis, provided evidence that Copaxone ( Glatiramer ) may offer protection from axonal injury and ... - Xagena.it

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional